AI can transform drug discovery only when its strengths are properly leveraged

The article notes a split narrative in the industry, with some headlines promising AI will speed drugs to market while others warn it could waste resources.

Thomas M. Kaiser, a medicinal chemist, physician and machine‑learning scientist, argues that AI will change how drugs are designed, but only if it is applied in ways that match its capabilities.

He points to foundation models and deep‑learning techniques as tools that can reshape natural, applied and clinical science, yet stresses they must be used under specific conditions to be effective.

The piece calls for a realistic discussion of AI’s limits and potential, suggesting that a measured approach could unlock genuine advances in drug discovery.